Monogram Biosciences, Inc., formerly ViroLogic, Inc., develops and commercializes diagnostic tests to help guide and improve the treatment of infectious diseases, cancer and other serious illnesses. The company's base business is HIV patient and pharmaceutical testing, where individualized medicine has been in practice for many years and is now an established reality. The recent name change reflects the company's broader commitment to extend its pioneering efforts in individualized medicine beyond viral diseases and into oncology and other serious diseases. Monogram's products are designed to help doctors optimize treatment regimens for their patients, which leads to better outcomes and reduced costs. Its technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines, in addition to targeted cancer therapeutics.
Keywords: epidermal growth factor receptor; genomics; personalized medicine; proteomics; resistance testing.